All Insights

Lilly's retatruitide hit 29% weight loss in Phase 2 — the highest ever recorded for an obesity drug — while AstraZeneca built the deepest ADC oncology platform through a Daiichi Sankyo partnership. Eight mega-cap pharma pipelines, ranked by which companies are building genuine scientific moats versus catching up from behind.

Biotech ETFs have underperformed the S&P 500 over both 5- and 10-year periods, with far more volatility — yet the sector still produces 3-20x returns for selective investors. Five distinct return mechanisms explain the paradox, ranked from accessible to non-scientists (M&A basket positioning) to requiring genuine scientific literacy (platform discount investing).

ARKG surged 185% in 2020, then fell 75% peak-to-trough — the most dramatic boom-bust cycle among the four major biotech ETFs. A composition and returns breakdown of XBI, IBB, ARKG, and BBH, mapped to which investor profile each one actually fits.

LLY and AZN delivered 25-40% annualized returns over a decade while PFE and NVO badly trailed the S&P 500 — proof that pharma sector exposure matters far less than stock selection. A complete framework covering mega-cap divergence, the structural $300B M&A tailwind facing small/mid-cap biotechs, and five distinct exit pathways beyond acquisition.

LLY, AZN, and ABBV significantly outperformed the S&P 500 over 5-10 years; JNJ, NVO, and PFE meaningfully lagged — with LLY's two GLP-1 drugs alone now over 60% of revenue. A full benchmark of all eight mega-cap pharma names, and why passive sector exposure has badly underperformed disciplined stock selection.

Investing in Roche, AstraZeneca, and Eli Lilly captures both the biology wave and the AI productivity wave — without paying the 35x P/E premium of pure-play AI stocks. A dimension-by-dimension comparison of AI/tech vs. pharma, ending in a specific 40-60% allocation recommendation.

All three portfolios — Income & Stability, Balanced Growth, High Conviction — target positive long-term returns; the only real difference is how those returns arrive: dividend income or capital appreciation. Specific allocations, projected returns, and rebalancing triggers for each risk profile.

Four BUYs (AstraZeneca, Merck, Roche, Eli Lilly), four HOLDs, zero SELLs — a full verdict on eight leading pharma companies, scored across pipeline strength, financial health, valuation, and patent cliff exposure as of April 2026.

The $1M HNWI threshold that legally qualifies you for venture capital is nearly irrelevant to whether you should actually participate. Real portfolio math puts the practical floor at $10M net worth, with genuine comfort starting around $25-50M+ — and the gap between "eligible" and "appropriate" is where a lot of costly mistakes happen.

A $500M fund returning $2B in profits generates $300M in carry — but GPs only get paid after LPs recover their full capital first. Why the "VCs invest their own money" assumption is wrong, and what that fiduciary structure actually means for founders, LPs, and anyone trying to break into venture.